메뉴 건너뛰기




Volumn 26, Issue 29, 2008, Pages 4843-4844

DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLIAL FIBRILLARY ACIDIC PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE;

EID: 54249143179     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.1776     Document Type: Article
Times cited : (5)

References (7)
  • 1
    • 2942532908 scopus 로고    scopus 로고
    • One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
    • Wick W, Steinbach JP, Kuker WM, et al: One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113-2115, 2004
    • (2004) Neurology , vol.62 , pp. 2113-2115
    • Wick, W.1    Steinbach, J.P.2    Kuker, W.M.3
  • 2
    • 34249818466 scopus 로고    scopus 로고
    • Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
    • Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986-2991, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 2986-2991
    • Ekeblad, S.1    Sundin, A.2    Janson, E.T.3
  • 3
    • 34447314728 scopus 로고    scopus 로고
    • MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
    • Kaina B, Christmann M, Naumann S, et al: MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6:1079-1099, 2007
    • (2007) DNA Repair (Amst) , vol.6 , pp. 1079-1099
    • Kaina, B.1    Christmann, M.2    Naumann, S.3
  • 4
    • 33847400183 scopus 로고    scopus 로고
    • MGMT methylation status: The advent of stratified therapy in glioblastoma?
    • Hau P, Stupp R: MGMT methylation status: The advent of stratified therapy in glioblastoma? Dis Markers 23:97-104, 2007
    • (2007) Dis Markers , vol.23 , pp. 97-104
    • Hau, P.1    Stupp, R.2
  • 5
    • 34848875420 scopus 로고    scopus 로고
    • Molecular genetic markers as predictors of response to chemotherapy in gliomas
    • Idbaih A, Omuro A, Ducray F, et al: Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 19:606-611, 2007
    • (2007) Curr Opin Oncol , vol.19 , pp. 606-611
    • Idbaih, A.1    Omuro, A.2    Ducray, F.3
  • 6
    • 20044372154 scopus 로고    scopus 로고
    • MGMT gene silencing and benefit from temozolomide in glioblastoma
    • Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
    • (2005) N Engl J Med , vol.352 , pp. 997-1003
    • Hegi, M.E.1    Diserens, A.C.2    Gorlia, T.3
  • 7
    • 46849085698 scopus 로고    scopus 로고
    • Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET)
    • abstr 4505, 18s
    • Kulke MH, Frauenhoffer CS, Hooshmand SM, et al: Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET). J Clin Oncol 25:18s, 2007 (abstr 4505)
    • (2007) J Clin Oncol , vol.25
    • Kulke, M.H.1    Frauenhoffer, C.S.2    Hooshmand, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.